Targeted α-particle therapy of bone metastases in prostate cancer

Clinical Nuclear Medicine

Volumn 38, Issue 12, 2013, Pages 966-971

  Jadvar, Hossein ^a   Quinn, David I ^b  

^a Division of Nuclear Medicine   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

>; ALSYMPCA; cancer; prostate; radium; therapy

Indexed keywords

ABIRATERONE ACETATE; ACTINIUM 225; BISMUTH 212; BISMUTH 213; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; LEAD 212; PHOSPHORUS 32; PLACEBO; PREDNISONE; RADIOISOTOPE; RADIUM CHLORIDE RA 223; RHENIUM 186; RHENIUM 188; SAMARIUM 153; SIPULEUCEL T; STRONTIUM 89; TERBIUM 149; TIN 117M; UNCLASSIFIED DRUG;

ALPHA RADIATION; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ALPHA PARTICLES; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOMETRY; RADON;

EID: 84888303650     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000290     Document Type: Article

References (68)

1. Zimmermann RG. Why are investors not interested in my radiotracer? The industrial and regulatory constraints in the development of radiopharmaceuticals. Nucl Med Biol. 2013;40:155-166.
2. Allen BJ. Clinical trials of targeted alpha therapy for cancer. Rev Recent Clin Trials. 2008;3:185-191.
3. Allen BJ. Future prospects for targeted alpha therapy. Curr Radiopharm. 2011;4:336-342.
4. Allen BJ. Targeted alpha therapy: evidence for potential efficacy of alphaimmunoconjugates in the management of micrometastatic cancer. Australas Radiol. 1999;43:480-486.
5. Mulford D, Scheinberg DA, Jurcic JG. The promise of targeted alpha-particle therapy. J Nucl Med. 2005;46:199SY204S.
6. Brechbiel MW. Targeted alpha-therapy: past, present, future? Dalton Trans. 2007;43:4918-4928.
7. Vaidyanathan G, Zalutsky MR. Targeted therapy using alpha emitters. Phys Med Biol. 1996;41:1915-1931.
8. Vaidyanathan G, Zalutsky MR. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Curr Radiopharm. 2011;4:283-294.
9. Sgourous G. Alpha particles for targeted therapy. Adv Drug Deliv Rev. 2008;60:1402-1406.
10. Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumor Biol. 2012;33:573-590.
11. Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008;38:358-366.
12. Humm JL, Rueske JC, Fisher DR, et al. Microdosimetric concepts in radioimmunotherapy. Med Phys. 1993;20:535-541.
13. Logothetis CJ, Gallick GE, Maity SN, et al. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013;3:849-861.
14. FDA Approves New Drug for Advanced Prostate Cancer. US Food and Drug Administration. Available at: http://www. fda. gov/NewsEvents/Newsroom/ PressAnnouncements/ucm352363. htm. Accessed May 15, 2013.
15. Mould RF, Robison RF, Tiggelen RV. Louis-Frédéric Wickham (1861-1913): father of radium therapy. J Oncol. 2010;60:79eY103e.
16. Quick D. Radium in cancer therapy. Br Med J. 1930;2:765-769.
17. Quick D. The influence of radium in cancer therapy. Can Med Assoc J. 1954;71:103-109.
18. Vapiwala N, Glatstein E. Fighting prostate cancer with Radium-223Vnot your Madame's isotope. N Engl J Med. 2013;369:276-278.
19. SEER Stat Fact Sheets: Prostate. National Cancer Institute Website. Available at: http://seercancer. gov/statfacts/html/prost. html. Accessed June 5, 2013.
20. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical TrialsWorking Group. J Clin Oncol. 2008;26:1148-1159.
21. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036-1042.
22. Fox JJ, Morris MJ, Larson SM, et al. Developing imaging strategies for castration resistant prostate cancer. Acta Oncol. 2011;50:39-48.
23. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
24. Lange PH, Vessella Rl. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1998;17: 331-336.
25. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578-583.
26. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
27. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
28. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus carbazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376: 1147-1154.
29. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
30. Yap TA, Zivi A, Omlin A, et al. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8:597-610.
31. Choudhury AD, Kantoff PW. New agents in metastatic prostate cancer. J Natl Compr Canc Netw. 2012;10:1403-1409.
32. Ohlmann CH, Merseburger AS, Suttmann H, et al. Novel options for the treatment of castration-resistant prostate cancer. World J Urol. 2012;30: 495-503.
33. Rescigno P, Buonerba C, Bellmunt J, et al. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets. 2012;13:1676-1686.
34. Fizazi K, Albiges L, Massard C, et al. Novel and bone-targeted agents for CRPC. Ann Oncol. 2012;23(suppl 10):x264Yx267.
35. Agarwal N, Sonpavde G, Sternberg CN. Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol. 2012;61:950-960.
36. Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61:549-559.
37. George D, Moul JW. Emerging treatment options for patients with castrationresistant prostate cancer. Prostate. 2012;72:338-349.
38. Higano CS, Crawford ED. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol. 2011; 29:S1YS8.
39. Pinski J, Dorff TB. Prostate cancer metastases to bone: pathophysiology, pain management, and the premise of targeted therapy. Eur J Cancer. 2005;41:932-940.
40. Jansen DR, Krijger GC, Kolar ZI, et al. Targeted radiotherapy of bone malignancies. Curr Drug Discov Technol. 2010;7:233-246.
41. Lewington V. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46: 38SY47S.
42. Autio KA, Scher HI, Morris MJ. Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Curr Treat Options Oncol. 2012;13: 174-188.
43. Bruland O, Nilsson S, Fisher DR, et al. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250sY6257s.
44. Cheetham PJ, Petrylak DP. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection. Oncology (Williston Park). 2012;26: 330-337, 341.
45. Crawford ED, Kozlowski JM, Debruyne FM, et al. The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology. 1994;44:481-485.
46. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357:336-341.
47. Brady D, Parker C, O'Sullivan JM. Bone targeting radiopharmaceuticals including radium-223. Cancer J. 2013;19:71-78.
48. Hafeez S, Parker C. Radium-223 for the treatment of prostate cancer. Expert Opin Investig Drugs. 2013;22:379-387
49. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011;29:3705-3714.
50. Henriksen G, Fisher DR, Roeske JC, et al. targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44:252-259.
51. Sartor O, Hoskin P, Bruland OS. Targeted radionuclide therapy of skeletal metastases. Cancer Treat Rev. 2013;39:18-26.
52. Harrison MR,Wong TZ, Armstrong AJ, et al. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5:1-14.
53. Li Y, Russell PJ, Allen BJ. Targeted alpha-therapy for control of micrometastatic prostate cancer. Expert Rev Anticancer Ther. 2004;4:459-468.
54. Liepe K. Alpharadin, a 223Ra-based alpha particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs. 2009;10:1346-1358.
55. Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomized, multicenter, placebocontrolled phase II study. Lancet Oncol. 2007;8:587-594.
56. Nilsson S, Larsen RH, FossûËSD, et al. First clinical experience with alphaemitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451-4459.
57. Nilsson S, Franzén L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013;11:20-26.
58. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678-686.
59. Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dosefinding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63:189-197.
60. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter Radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
61. Hindorf C, Chittenden S, Aksenes AK, et al. Quantitative imaging of 223Rachloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun. 2012;33:726-732.
62. Cook G Jr, Parker C, Chua S, et al. 18F-fluoride PET: changes in uptake as a method to assess response to bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chlroide (Alpharadin). EJNMMI Res. 2011;1:4.
63. Licensing Decision for Radium-223 Dichloride. United States Nuclear Regulatory Commission. NUREG/BR-0117; No. 13-01. Available at: http:// www. nrc. gov/reading-rm/doc-collections/nuregs/brochures/br0117/13-01. pdf Accessed August 16, 2013. .
64. Lassmann M, Nosske D. Dosimetry of (223)Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40:207-212.
65. Hobbs RF, Song H, Watchman CJ, et al. A bone marrow toxicity model for 223Ra alpha emitter radiopharmaceutical therapy. Phys Med Biol. 2012;57: 3207-3222.
66. Chouin N, Bardies M. Alpha particle microdosimetry. Curr Radiopharm. 2011;4:266-280.
67. Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, et al. Phase I pahramacoknietic and biodistribution study with escalating doses of 223 Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1384-1393.
68. Hooper S. http://www. npl. co. uk/upload/pdf/20070131-rcuf-hooper-1. pdf.